曲美他嗪治疗高血压性心脏病的临床效果

Abstract
Figure/Table
References (23)
Related Citation (15)

Download: PDF (444 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the clinical effect of Trimetazidine in the treatment of hypertensive heart disease. Methods A total of 80 patients with hypertensive heart disease admitted to Haikou Hospital Affiliated to Xiangya Hospital Central South University were selected as the research object. According to the random number table method, they were divided into experimental group and routine group, with 40 cases in each group. The conventional group was treated with conventional therapy, and the experimental group was treated with Trimetazidine Tablets on the basis of the conventional group. The dosage of Trimetazidine Tablets was 20 mg/time, 3 times/day, and the patients in both groups were treated for 3 months. Clinical treatment effect, clinical symptoms, cardiac function changes and adverse symptoms were compared between the two groups. Results After treatment, the overall productivity of the experimental group was higher than that of the conventional group, and the difference was statistically significant (P ＜ 0.05). After treatment, the frequency of angina pectoris, the duration of angina pectoris and the amount of nitroglycerin used in the experimental group were all lower than those in the conventional group, and the amount of exercise for 7 min was higher than that in the conventional group, with statistically significant differences (all P ＜ 0.05). Before treatment, there was no statistically significant difference in left ventricular ejection fraction (LVEF), left ventricular end-systolic volume index (LVESVI) and left ventricular end-diastolic volume index (LVEDVI) between the two groups (P ＞ 0.05). After treatment, LVEF in the two groups was higher than that before treatment, LVESVI and LVEDVI were lower than those before treatment, and LVEF in the experimental group was higher than that in the conventional group, and LVESVI and LVEDVI were lower than those in the conventional group, with statistically significant differences (all P ＜ 0.05). During the treatment period, there was no statistically significant difference in the incidence of adverse symptoms between the two groups (P ＞ 0.05). Conclusion The use of Trimetazidine on the basis of conventional drug treatment can significantly increase the curative effect of patients with hypertensive heart disease, can significantly reduce the frequency of angina pectoris and the amount of nitroglycerin, can under the premise of the control of blood pressure, make the patient′s heart function and exercise were promoted, so as to improve the prognosis of patients.

Key words： Nitroglycerin Trimetazidine Angina pectoris Hypertensive heart disease

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YANG Hui ZHONG Jianghua SU Yujiang MA Tianyi

Cite this article:

YANG Hui ZHONG Jianghua SU Yujiang MA Tianyi. Clinical effect of Trimetazidine in the treatment of hypertensive heart disease[J]. 中国医药导报, 2020, 17(10): 149-152.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I10/149

[1] Marzilli M，Merz CN，Boden WE，et al. Obstructive coronary atherosclerosis and ischemic heart disease：an elusive link![J]. J Am Coll Cardiol，2012，60（11）： 951-956.
[2] Wong MC，Zhang DX，Wang HH. Rapid emergence of atherosclerosis in Asia：a systematic review of coronary atherosclerotic heart disease epidemiology and implications for prevention and control strategies [J]. Curr OpinLipidol，2015，26（4）：257-269.
[3] Budoff MJ，Young R，Lopez VA，et al. Progression of coronary calcium and incident coronary heart disease events： MESA（Multi-Ethnic Study of Atherosclerosis）[J]. J Am Coll Cardiol，2013，61（12）：1231-1239.
[4] Task Force Members，Montalescot G，Sechtem U，et al. 2013 ESC guidelines on the management of stable coronary artery disease：the Task Force on the management of stable coronary artery disease of the European Society of Cardiology [J]. Eur Heart J，2013，34（38）：2949-3003.
[5] 石责江，黄修平，邱承毅，等.曲美他嗪对老年冠心病心力衰竭患者左室功能的影响[J].中国老年学杂志，2011，31（16）：3155-3156.
[6] CSC.2016：中国高血压防治指南修订问题的解读[J].实用心脑肺血管病杂志，2016，24（9）：24.
[7] 王丽萍.厄贝沙坦联合美托洛尔治疗高血压心脏病的临床效果及不良反应分析[J].吉林医学，2019，40（7）：1506-1507.
[8] 王锁柱，陈炜，陆非平，等.缬沙坦联合辅酶Q10对高血压心脏病患者炎症及氧化应激水平的影响[J].中华高血压杂志，2019，27（6）：566-570.
[9] 魏景美，汪晓洲.缬沙坦联合卡托普利治疗老年高血压患者的临床效果[J].中国医药导报，2019，16（7）：88-91.
[10] 蔡旭阳，金朝辉，吴斌，等.曲美他嗪联合美托洛尔治疗冠心病伴心力衰竭效果和安全性的系统评价[J].中国医药导报，2019，16（7）：136-139.
[11] 许卫国.阿托伐他汀联合曲美他嗪治疗冠心病对患者血脂及心功能的影响[J].临床医药实践，2019，28（10）：731-733，741.
[12] Lopatin YM，Rosano GM，Fragasso G，et al. Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure [J]. Int J Cardiol，2016，203：909-915.
[13] Tsioufis K，Andrikopoulos G，Manolis A. Trimetazidine and cardioprotection：facts and perspectives [J]. Angiology，2015，66（3）：204-210.
[14] Ferraro E，Pin F，Gorini S，et al. Improvement of skeletal muscle performance in ageing by the metabolic modulator Trimetazidine [J]. J Cachexia Sarcopenia Muscle，2016，7（4）：449-457.
[15] 邹艳慧.曲美他嗪治疗老年冠状动脉粥样硬化性心脏病伴高血压性心脏病的效果观察[J].世界最新医学信息文摘，2019，19（69）：9-10.
[16] 於忠伟.曲美他嗪联合卡维地洛对高血压心脏病慢性心力衰竭患者的影响[J].中国现代医生，2018，56（18）：30-33，37.
[17] 梁国君，廖桂华.美托洛尔联合曲美他嗪对老年高血压合并慢性心力衰竭患者的疗效[J].中国医药，2019，14（2）：179-182.
[18] 黄浪，许光宇，罗卫华，等.曲美他嗪联合美托洛尔治疗高血压性心脏病临床研究[J].中国药业，2019，28（4）：54-56.
[19] 陈桂坚，彭志坚，章少波，等.曲美他嗪联合磷酸肌酸钠治疗冠心病合并慢性左心功能不全的临床观察[J].中国医药科学，2018，8（5）：82-84，107.
[20] Magnussen CG. Carotid artery intima-media thickness and hypertensive heart disease：a short review [J]. J Clin Hypertens，2017，23（1）：7.
[21] Ferrara F，Gargani L，Ostenfeld E，et al. Imaging the right heart pulmonary circulation unit： Insights from advanced ultrasound techniques[J]. Echocardiography，2017，34（8）：1216-1231.
[22] 崔晓博.曲美他嗪对高血压性心脏病患者炎性因子及心肌重构的影响[J].河北医学，2018，24（7）：1204-1207.
[23] 杨婷，赵茜茜，崔晓博，等.曲美他嗪联合卡维地洛对高血压心脏病慢性心力衰竭患者心功能及N末端脑钠肽前体、肌钙蛋白Ⅰ的影响[J].安徽医药，2018，22（5）：971-974.